Alzheimer's Disease: Drug Discovery
Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15...
Na minha lista:
| Formato: | Online |
|---|---|
| Idioma: | inglês |
| Publicado em: |
Exon Publications
2022
|
| Assuntos: | |
| Acesso em linha: | https://directory.doabooks.org/handle/20.500.12854/81835.3 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869527713529724928 |
|---|---|
| collection | Directory of Open Access Books |
| description | Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15 years of progressive course. Unfortunately, there are neither effective preventive measures nor efficacious treatments available for this devastating disease. Such a situation undoubtedly calls for the diversification of druggable targets for Alzheimer’s disease and a search for poly-targets or drug combination therapeutic strategies. Contributed by an assembly of clinicians and translational and basic research scientists, this book intends to provide an overview of the current state and future perspectives of Alzheimer’s disease drug discovery. It covers the underlying pathogenic mechanisms of Alzheimer’s disease and provides a review of Aβ amyloid- and τ protein-targeted immunotherapies, and peptide inhibitors for anti-Aβ amyloidosis. In addition, it also examines therapeutic potentials of various Alzheimer’s disease drug targets such as brain metal homeostasis, protein kinase C, the blood-brain barrier, epigenetic therapies, as well as discusses chimeric conjugates, multifunctional ligands, and natural products as interventional approaches. This book will be valuable to healthcare professionals caring for patients, researchers and interested readers as it will provoke thoughts about identifying novel and more efficacious therapeutic agents for Alzheimer’s disease and related dementias. |
| format | Online |
| id | doab-20.500.12854ir-81835.3 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | Exon Publications |
| publisherStr | Exon Publications |
| record_format | ojs |
| spelling | doab-20.500.12854ir-81835.32022-05-21T22:51:14Z Alzheimer's Disease: Drug Discovery Huang, Xudong Etiology of Alzheimer’s Disease; Epidemiology of Alzheimer’s Disease; Neuropathology of Alzheimer’s Disease; Pathogenesis of Alzheimer’s Disease; Immunotherapy for Alzheimer’s Disease; Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease; Tau Protein-Targeted Therapies in Alzheimer’s Disease; Targeting Metal Homeostasis for Alzheimer’s Disease; Insulin-Resistant in Alzheimer’s Disease; Blood–Brain Barrier in Alzheimer’s Disease; Epigenetic Modifications in Alzheimer’s Disease; Chimeric Conjugates for Alzheimer’s Disease; Multifunctional Ligand Approach for Alzheimer’s Disease; Natural Products for Alzheimer’s Disease MJND Alzheimer’s disease is the most common cause of age-related dementia. Alzheimer’s disease presents with irreversible cognitive decline, which commences as insidious short-term memory dysfunction and gradually spreads to other cognitive domains, rendering patients mute and non-ambulatory after 10-15 years of progressive course. Unfortunately, there are neither effective preventive measures nor efficacious treatments available for this devastating disease. Such a situation undoubtedly calls for the diversification of druggable targets for Alzheimer’s disease and a search for poly-targets or drug combination therapeutic strategies. Contributed by an assembly of clinicians and translational and basic research scientists, this book intends to provide an overview of the current state and future perspectives of Alzheimer’s disease drug discovery. It covers the underlying pathogenic mechanisms of Alzheimer’s disease and provides a review of Aβ amyloid- and τ protein-targeted immunotherapies, and peptide inhibitors for anti-Aβ amyloidosis. In addition, it also examines therapeutic potentials of various Alzheimer’s disease drug targets such as brain metal homeostasis, protein kinase C, the blood-brain barrier, epigenetic therapies, as well as discusses chimeric conjugates, multifunctional ligands, and natural products as interventional approaches. This book will be valuable to healthcare professionals caring for patients, researchers and interested readers as it will provoke thoughts about identifying novel and more efficacious therapeutic agents for Alzheimer’s disease and related dementias. Published 2022-05-21T22:51:12Z 2022-05-21T22:16:03Z 2022-05-21T22:43:35Z 2022-05-21T22:51:12Z 2020-12-19 book 9780645001709 https://directory.doabooks.org/handle/20.500.12854/81835.3 eng image/jpeg Attribution-NonCommercial-NoDerivatives 4.0 International https://exonpublications.com/index.php/exon/issue/view/12 Exon Publications 10.36255/exonpublications.alzheimersdisease.2020 10.36255/exonpublications.alzheimersdisease.2020 2d6001a3-9e06-4979-bf02-6974e313eb24 9780645001709 229 Australia open access |
| spellingShingle | Etiology of Alzheimer’s Disease; Epidemiology of Alzheimer’s Disease; Neuropathology of Alzheimer’s Disease; Pathogenesis of Alzheimer’s Disease; Immunotherapy for Alzheimer’s Disease; Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease; Tau Protein-Targeted Therapies in Alzheimer’s Disease; Targeting Metal Homeostasis for Alzheimer’s Disease; Insulin-Resistant in Alzheimer’s Disease; Blood–Brain Barrier in Alzheimer’s Disease; Epigenetic Modifications in Alzheimer’s Disease; Chimeric Conjugates for Alzheimer’s Disease; Multifunctional Ligand Approach for Alzheimer’s Disease; Natural Products for Alzheimer’s Disease MJND Alzheimer's Disease: Drug Discovery |
| title | Alzheimer's Disease: Drug Discovery |
| title_full | Alzheimer's Disease: Drug Discovery |
| title_fullStr | Alzheimer's Disease: Drug Discovery |
| title_full_unstemmed | Alzheimer's Disease: Drug Discovery |
| title_short | Alzheimer's Disease: Drug Discovery |
| title_sort | alzheimer s disease drug discovery |
| topic | Etiology of Alzheimer’s Disease; Epidemiology of Alzheimer’s Disease; Neuropathology of Alzheimer’s Disease; Pathogenesis of Alzheimer’s Disease; Immunotherapy for Alzheimer’s Disease; Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease; Tau Protein-Targeted Therapies in Alzheimer’s Disease; Targeting Metal Homeostasis for Alzheimer’s Disease; Insulin-Resistant in Alzheimer’s Disease; Blood–Brain Barrier in Alzheimer’s Disease; Epigenetic Modifications in Alzheimer’s Disease; Chimeric Conjugates for Alzheimer’s Disease; Multifunctional Ligand Approach for Alzheimer’s Disease; Natural Products for Alzheimer’s Disease MJND |
| topic_facet | Etiology of Alzheimer’s Disease; Epidemiology of Alzheimer’s Disease; Neuropathology of Alzheimer’s Disease; Pathogenesis of Alzheimer’s Disease; Immunotherapy for Alzheimer’s Disease; Amyloid β-Targeted Inhibitory Peptides for Alzheimer’s Disease; Tau Protein-Targeted Therapies in Alzheimer’s Disease; Targeting Metal Homeostasis for Alzheimer’s Disease; Insulin-Resistant in Alzheimer’s Disease; Blood–Brain Barrier in Alzheimer’s Disease; Epigenetic Modifications in Alzheimer’s Disease; Chimeric Conjugates for Alzheimer’s Disease; Multifunctional Ligand Approach for Alzheimer’s Disease; Natural Products for Alzheimer’s Disease MJND |
| url | https://directory.doabooks.org/handle/20.500.12854/81835.3 |